Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors

Antonio M. Risitano, Austin Kulasekararaj, Phillip Scheinberg, Alexander Röth, Bing Han, Jaroslaw P. Maciejewski, Yasutaka Ueda, Carlos M. de Castro, Eros Di Bona, Rong Fu, Zhang Li, Morag Griffin, Saskia Langemeijer, Jens Panse, Hubert Schrezenmeier, Wilma Barcellini, Vitor AQ Mauad, Philippe Schafhausen, Suzanne Tavitian, Eloise Beggiato, Lee Ping Chew, Anna Gayà, Wei‐Han Huang, Jun Ho Jang, Toshio Heike, Abdullah Kutlar, Rosario Notaro, Vinod Pullarkat, Jörg Schubert, Louis Terriou, Michihiro Uchiyama, Lily Wong Lee Lee, Eng Soo Yap, Camilla Frieri, Luana Marano, Flore Sicre de Fontbrune, Shreyans Gandhi, Roochi Trikha, Ferras Alashkar, Yang Chen, Hui Liu, Richard Kelly, Britta Höchsmann, Tomasz Lawniczek, Navin Mahajan, Susan Solar‐Yohay, Cécile Kerloëguen, Philippe Ferber, Rakesh Kumar, Zhixin Wang, Christine Thorburn, Samopriyo Maitra, Shujie Li, Aurélie Verles, Marion Dahlke, Régis Peffault de Latour